INCY logo

Incyte Corporation

INCY
Healthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97
Next Earnings Report
Feb 9, 2027
EPS est. $1.90 · Revenue est. $1.55B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (108)

Nov 2026
Est. completion
P2Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Dec 2026
Est. completion
P2Hodgkin Lymphoma
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Dec 2026
Est. completion
P2TNBC - Triple-Negative Breast Cancer
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Dec 2026
Est. completion
P1Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Dec 2026
Est. completion
P3Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Dec 2026
Est. completion
P2Advanced Pancreatic Carcinoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Dec 2026
Est. completion
P1P2CNS Lymphoma
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Dec 2026
Est. completion
Early P1Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Jan 2027
Est. completion
P2Large B-cell Lymphoma
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Jan 2027
Est. completion
P1Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Jan 2027
Est. completion
P2Splenomegaly
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Jan 2027
Est. completion
P1Myelofibrosis Due to and Following Polycythemia Vera
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Jan 2027
Est. completion
P1Chronic Lymphocytic Leukemia
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Jan 2027
Est. completion
P1Renal Impairment
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Jan 2027
Est. completion
P1P2Chronic Graft-versus-host-disease
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Jan 2027
Est. completion
P2Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Feb 2027
Est. completion
P2Diffuse Large B Cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Feb 2027
Est. completion
P2Non-Hodgkin Lymphoma
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Awaiting Results (31)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
NCT07448155
Nov 2026
P2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT04509700
Oct 2026
P3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965
Oct 2026
P3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952
Oct 2026
P3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211
Oct 2026
P3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225
Oct 2026
P2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564
Sep 2026
P2P3
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751
Sep 2026
P3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092
Aug 2026
P3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618

SEC Filings (49)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 31, 20268-KMaterial eventDocumentIndex
Jul 28, 202610-QQuarterly reportDocumentIndex
Jul 28, 20268-KMaterial eventDocumentIndex
Jul 6, 20268-KMaterial eventDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
Jun 8, 20268-KMaterial eventDocumentIndex
May 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 28, 202610-QQuarterly reportDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 6, 20268-KMaterial eventDocumentIndex
Feb 10, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Feb 10, 202610-KAnnual reportDocumentIndex
Feb 10, 20268-KMaterial eventDocumentIndex
Dec 12, 20258-KMaterial eventDocumentIndex
Nov 10, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 7, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 28, 202510-QQuarterly reportDocumentIndex
Oct 28, 20258-KMaterial eventDocumentIndex
Oct 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 3, 20258-KMaterial eventDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Jul 29, 202510-QQuarterly reportDocumentIndex
Jul 29, 20258-KMaterial eventDocumentIndex
Jul 2, 2025S-8Employee stock planDocumentIndex
Jun 27, 20258-KMaterial eventDocumentIndex
Jun 18, 2025S-8Employee stock planDocumentIndex
Jun 18, 2025S-8Employee stock planDocumentIndex
Jun 11, 20258-KMaterial eventDocumentIndex